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Abstract
Background: The availability of H5N1 vaccines that can elicit a broad cross-protective immunity against different currently
circulating clade 2 H5N1 viruses is a pre-requisite for the development of a successful pre-pandemic vaccination strategy. In
this regard, it has recently been shown that adjuvantation of a recombinant clade 1 H5N1 inactivated split-virion vaccine
with an oil-in-water emulsion-based adjuvant system also promoted cross-immunity against a recent clade 2 H5N1 isolate
(A/Indonesia/5/2005, subclade 2.1). Here we further analyse the cross-protective potential of the vaccine against two other
recent clade 2 isolates (A/turkey/Turkey/1/2005 and A/Anhui/1/2005 which are, as defined by WHO, representatives of
subclades 2.2 and 2.3 respectively).
Methods and Findings: Two doses of the recombinant A/Vietnam/1194/2004 (H5N1, clade 1) vaccine were administered 21
days apart to volunteers aged 18–60 years. We studied the cross-clade immunogenicity of the lowest antigen dose (3.8 mg
haemagglutinin) given with (N=20) or without adjuvant (N=20). Immune responses were assessed at 21 days following the
first and second vaccine doses and at 6 months following first vaccination. Vaccination with two doses of 3.8 mg of the
adjuvanted vaccine induced four-fold neutralising seroconversion rates in 85% of subjects against A/turkey/Turkey/1/2005
(subclade 2.2) and 75% of subjects against A/Anhui/1/2005 (subclade 2.3) recombinant strains. There was no response
induced against these strains in the non-adjuvanted group. At 6 months following vaccination, 70% and 60% of subjects
retained neutralising antibodies against the recombinant subclade 2.2 and 2.3 strains, respectively and 40% of subjects
retained antibodies against the recombinant subclade 2.1 A/Indonesia/5/2005 strain.
Conclusions: In addition to antigen dose-sparing, adjuvantation of inactivated split H5N1 vaccine promotes broad and
persistent cross-clade immunity which is a pre-requisite for a pre-pandemic vaccine.
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Introduction
It is widely feared that the ongoing global spread of the highly
pathogenic avian H5N1 influenza virus in wild birds and poultry
will trigger the next human influenza pandemic [1–7]. The H5N1
virus currently fulfils two of the three pre-requisites for a global
influenza pandemic to occur [1]. First H5 is a new haemagglutinin
(HA) subtype to which virtually the entire human population lacks
immunity. Second the virus can replicate in humans and cause
serious illness and death. The first human disease caused by H5N1
was reported in Hong Kong in 1997 with eighteen cases and six
deaths [8–10] and the virus has continued to be associated with a
high case–fatality rate [11]. Up until now, human cases have only
been caused by close contact with animals (mainly poultry)
infected with the virus. Although there have been isolated reports
of transmission from one human to another [12,13] the H5N1
virus does not currently fulfil the third pandemic pre-requisite
which is sustained human-to-human transmission. Nevertheless
the endemicity of H5N1 in poultry in many areas and the
expansion of its avian and mammalian host range are providing
more opportunities for human exposure [1]. This in turn increases
the risk of reassortment or direct mutation into a virus better
adapted for human transmission.
In the event of a pandemic, vaccination is universally regarded as
the most important public health intervention for preventing
influenza and reducing its health consequences [14–16]. The use of
reverse genetics to remove the H5 polybasic amino acid sequence
associated with pathogenicity has enabled production of prototype
reassortant H5N1 vaccine strains containing H5 and N1 gene
segments inserted into a backbone containing the other six influenza
genesfromPR8,alaboratoryadaptedavirulentH1N1strain[17,18].
Several H5N1 vaccines have been developed [19–23] and two
vaccines (one split-virion [19] and one whole-virion [22]) have
already been licensed [24,25]. Indeed, many countries are now
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vaccine stockpiles will be severely constrained by the lack of
sufficient H5 vaccine antigen due to limited global production
capacity. High priority has thus been given to the investigation of
strategies that economize on the use of antigen such as improving
immunogenicity by adjuvantation [14]. Our group recently reported
on the safety and immunogenicity of an adjuvanted inactivated split-
virion A/Vietnam/1194/2004 (clade 1) H5N1 candidate vaccine
[23]. This study was the first to show a significant antigen dose-
sparing effectinduced bythe inclusion of a novel adjuvant [23]. Two
adjuvanted doses containing only 3.8 mg HA were found to be
sufficiently immunogenic to comply with licensure criteria set out by
the CHMP [15] and FDA [16]. This HA dose is more than 20 fold
less than the 90 mg dose required for the H5N1 inactivated split-
virion vaccine approved by the FDA [19,25].
Another significant finding in this study was that the adjuvant also
enhanced cross-reactive immunity of the A/Vietnam/1194/2004
vaccine against a prototype strain derived from the more recent
H5N1 drift strain A/Indonesia/5/2005. Phylogenetic and antigenic
analyses of the HA of H5N1 viruses collected since 1997 indicate
that they have evolved into different sublineages or clades [18]. As
we cannot predict the evolution of the H5 HA or which strain will
become pandemic it will not be possible to develop a vaccine
matching the actual pandemic strain for several months after its
emergence. This means that advance stockpiling of vaccine is only
useful if the vaccine can elicit a broad cross-protective immunity
against different H5N1 viruses, including newly emerged strains.
Analysis of the HA sequences of H5N1 isolates collected between
August 2006 and March 2007 indicate that the majority belong to
clades 1 and 2 [18]. Clade 1 viruses were found in Cambodia,
Thailand and Vietnam while clade 2 viruses circulated in China and
Indonesia later spreading to the Middle East, Europe and Africa.
Furthermore, multiple subclades of clade 2 have been distinguished,
three of which (clades 2.1, 2.2 and 2.3) have so far been largely
responsible for human cases [18]. The recombinant A/Indonesia/
5/2005 H5N1 strain used to assess cross-immunity in our previous
report [23] belongs to clade 2.1.
Here we report on further analysis of the cross-protective
potential of the candidate adjuvanted clade 1 A/Vietnam/1194/
2004 vaccine and demonstrate induction of cross-clade immunity
against reassortant H5N1 strains derived from clade 2.2 (A/
turkey/Turkey/1/2005) and clade 2.3 (A/Anhui/1/2005) viruses
as currently recommended by WHO [18]. Furthermore, we
demonstrate the persistence of cross-immunity against all three
clade 2 subclades at six months following vaccination.
Methods
The CONSORT checklist and flowchart are available as
supporting information; please see Checklist S1 and Flowchart S1.
We conducted a randomised, observer-blind clinical trial to assess
the safety and immunogenicity of an inactivated split A/Vietnam/
1194/2004 NIBRG-14 (recombinant H5N1 engineered by reverse
genetics obtained from the National Institute for Biological
Standards and Control (NIBSC), Potters Bar, UK) vaccine (manu-
factured by GlaxoSmithKline (GSK) Biologicals, Dresden, Ger-
many). Two doses of the vaccine were administered 21 days apart to
eight groups of 50 healthy male and female volunteers aged 18–
60 years. Four HA antigen doses (3.8 mg, 7.5 mg, 15 mgo r3 0mg)
were given with or without an oil-in-water emulsion based adjuvant
system[23].ThestudywasconductedattheCentreforVaccinology,
Ghent University and Hospital, Ghent, Belgium and is registered
with the ClinicalTrials.gov registry (number NCT00309634).
Written informed consent was obtained from all participants.
A detailed account of the study methodology has been published
along with the results for the co-primary objectives (safety and
humoral immune response) including data on cross-reactive
immunogenicity induced by the low antigen dose formulations
(containing 3.8 mg and 7.5 mg HA) against a heterologous strain
derived by reverse genetics from the drifted clade 2 H5N1 virus, A/
Indonesia/5/2005 (subclade 2.1) [23]. This present report evaluates
the cross-reactive immunogenicity induced by the adjuvanted and
non-adjuvanted 3.8 mg HA formulations against further heterolo-
gous strains derived by reverse genetics from drifted clade 2 H5N1
viruses A/turkey/Turkey/1/2005 (subclade 2.2, provided by
NIBSC, Potters Bar, UK) and A/Anhui/1/2005 (subclade 2.3,
provided by the Centers for Disease Control and Prevention,
Atlanta, USA). Data are also presented on the persistence of cross-
reactive antibodies against all three heterologous clade 2 H5N1
strains, which are currently recommended for use in vaccine
development by WHO [18]. Cross-reactive immunogenicity was
assessed by neutralisation and haemagglutination-inhibition (HAI)
assays (performed as described previously [23]) on serum samples
obtained at 21 days following the first vaccine dose (day 21), at
21 days following the second vaccine dose (day 42) and at
approximately 6 months following vaccination (day 180).
We summarised cross-reactive immunogenicity in a subset of
subjects from the per protocol population. The endpoints were
neutralising seroconversion rate (at least a four-fold increase in
titre relative to the pre-vaccination titre), the percentage of subjects
with post-vaccination HAI titre $1:40 (deemed to be the
seroprotective threshold for seasonal influenza vaccines) and
geometric mean titres (GMTs) at each time point (with 95% CI).
Role of the funding source
GSK Biologicals was the funding source and was involved in all
stagesofthestudyconductandanalysis.GSKBiologicalsalsotookin
charge all cost associated to the development and the publishing of
the present manuscript. The corresponding author had full access to
the data and had final responsibility to submit for publication.
Results
Four hundred adults were enrolled into the study and randomised
totheeightvaccinegroups,allreceived thetwo plannedvaccinations
and completed the study [23]. In the two study groups (non-
adjuvanted 3.8 mg HA dose and adjuvanted 3.8 mgH Ad o s e )w h i c h
this report focuses on, all but one subject (who did not comply with
the blood sampling schedule) were included in the per protocol
cohort giving 50 subjects per group. Of these, a subset of 20 subjects
from each group, selected only on the basis of the availability of a
sufficient volume of serum for testing were analysed for immune
responses against the recombinant A/turkey/Turkey/1/2005 and
A/Anhui/1/2005 clade 2 strains. It should be noted that 43 subjects
from the non-adjuvanted 3.8 mgH Ag r o u pa n d4 8f r o mt h e
adjuvanted 3.8 mg HA group had previously been analysed for
immune responses against the recombinant A/Indonesia/5/2005
clade 2 strain [23]. In this report we again present the A/Indonesia/
5/2005 neutralising data, but only for the 20 subjects also analysed
against the other clade 2 strains. The median ages (27 and 28 years)
and gender ratios (75% and 80%female) of the subset populations in
each group were similar. All subjects were white Caucasian.
Figure 1 (seroconversion rates) and Figure 2 (GMTs) present the
cross-neutralising responses after the first (day 21) and second (day
42) vaccine doses and at 6 months following vaccination (day 180).
Four-fold seroconversion responses were recorded against all three
recombinant clade 2 strains in the adjuvanted group while there was
no response against any of the three strains in the non-adjuvanted
Cross-Reactive H5N1 Vaccine
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for the recombinant subclade 2.2 A/turkey/Turkey/1/2005 (45%)
and subclade 2.3 A/Anhui/1/2005 (35%) strains. A 10% serocon-
version rate was recorded in the same subjects for the recombinant
subclade 2.1 A/Indonesia/5/2005 strain. Following the second
dose, seroconversion rates were similar (75%–85%) for all three
strains. In most of these subjects (60–70%) the cross-neutralising
response against the recombinant subclade 2.2 and 2.3 strains was
still evident at 6 months following vaccination, while at this time-
point 40% of subjects retained vaccine induced neutralising
antibodies against the recombinant subclade 2.1 strain.
The enhancing effect of the adjuvant on the cross-neutralising
responses is reflected in the GMTs against all three strains which
in the non-adjuvanted group remain at pre-vaccination levels
(below 20) at all time-points but in the adjuvanted group increase
to between 32 to 42 after the first dose and 80 to 113 after the
second dose. Again the persistence of cross-neutralising antibodies
against all three strains is evident from the GMTs at 6 months
following vaccination.
The HAI response (data not shown) was weaker than the
neutralising response with seroprotective HAI titres induced in
35% and 60% of subjects respectively for the A/Anhui/1/2005
and A/turkey/Turkey/1/2005 strains following the second dose.
Only one subject in the non-adjuvanted group had a seroprotec-
tive HAI titre against the A/turkey/Turkey/1/2005 strain.
Discussion
We have shown that the candidate clade 1 H5N1 inactivated
split-virion vaccine adjuvanted with an oil-in-water based
emulsion adjuvant system can induce neutralising antibodies
against recombinant strains derived from three recently emergent
clade 2 viruses belonging to different subclades. Furthermore, this
cross-clade immunity was induced at a low HA dose of 3.8 mg.
These results are encouraging, as they demonstrate that a vaccine
based on an existing H5N1 strain could potentially protect against
a range of different emerging H5N1 strains. This is the concept on
which the pre-pandemic immunisation strategy is based.
To be optimal for use in a pre-pandemic immunisation strategy,
we need vaccines that i) are safe, ii) are highly immunogenic, iii)
exhibit broad cross-immunity and iv) have long- lived immunity.
As with other split-virion or whole-virion H5N1 vaccines based on
strains derived by reverse genetics [19–22], the candidate
adjuvanted vaccine derived from the 2004 H5N1 isolate A/
Vietnam/1194/2004 seems to be well tolerated with an acceptable
safety profile [23]. The adjuvanted vaccine was also shown to be
highly immunogenic, a dose of 3.8 mg HA was sufficient to achieve
immunity against the vaccine strain at a level that was acceptable
for licensing in US and Europe [23]. An inactivated split-virion
H5N1 vaccine has been licensed by the FDA, however this
vaccine, which is administered without adjuvant is poorly
immunogenic [19,25]. Two 90 mg doses are needed to achieve
the level of immunity required for licensing compared to one dose
of 15 mg for conventional seasonal split-virion vaccines. Adjuvan-
tation with aluminium was shown to only modestly improve the
immunogenicity of inactivated split-virion H5N1 vaccine [20]
although more promising results were achieved with whole-virion
H5N1 vaccines administered with aluminium [21,22].
As previously reported [23], after 2 administrations of 3.8 mg
HA of the AS adjuvanted rH5N1 vaccine, 84% of the 50
volunteers presented seroprotective HAI titres against A/Viet-
nam/1194/2004 vaccine strain and 86% presented a four-fold
seroconversion rate for neutralising antibodies while in the group
of volunteers administered with the non-adjuvanted vaccine these
percentages were 4% and 22%, respectively [23].
In this report we now provide evidence that the adjuvanted
clade 1 candidate vaccine exhibits a broad cross-immunity against
Figure 1. Neutralising seroconversion rates to the heterolo-
gous recombinant A/Indonesia/5/2005, A/Anhui/1/2005 and A/
turkey/Turkey/1/2005 strains following vaccination with A/
Vietnam/1194/2004 NIBRG-14 vaccine.
doi:10.1371/journal.pone.0001665.g001
Figure 2. Neutralising geometric mean titres (GMTs) to the
heterologous recombinant A/Indonesia/5/2005, A/Anhui/1/
2005 and A/turkey/Turkey/1/2005 strains following vaccina-
tion with A/Vietnam/1194/2004 NIBRG-14 vaccine.
doi:10.1371/journal.pone.0001665.g002
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The effect of the oil-in-water emulsion based adjuvant system in
promoting this cross-immunity was contrasting with the absence of
a response in the non-adjuvanted group. We demonstrated that, in
addition to the recombinant subclade 2.1 A/Indonesia/5/2005
strain, the vaccine also induced neutralising antibodies against two
other recombinant strains derived from the recent drift H5N1
strains A/turkey/Turkey/1/2005 and A/Anhui/1/2005 which
are, as defined by WHO, representatives of subclades 2.2 and 2.3
respectively. The ability of the vaccine to induce immunity against
these three phylogenetic subclades is of relevance as, together with
clade 1, they account for the majority of recent circulating H5N1
isolates and also human H5N1 cases [18].
Following the first dose of the vaccine a neutralising response
against the subclades 2.2 and 2.3 was evidenced in 35%-45% of
subjects.It hasbeen estimated that a pandemic vaccine that provides
even partial cross-protection (about 30%) could have substantial
impact on attack rates [26,27]. Thus in a critical situation where
thereisnotsufficienttimeorsupplyofvaccinetoadministerasecond
dose, even one dose of the vaccine may help to reduce transmission
of the pandemic virus. A high level of cross-immunity (75%–85%)
against all three subclades was evident following the second dose.
Furthermore we provide evidence that this cross-clade immunity is
long-lived as it could still be detected in the majority of subjects at six
months following vaccination. The neutralising antibody titres
against A/Vietnam/1194/04 homologous virus follow the same
trend asthecross-reactive antibodytitresagainstclade2viruses(data
not shown, manuscript under preparation). Humoral immunity for
influenza vaccines has conventionally been assessed by HAI. Our
previous experience with A/Indonesia/5/2005 H5N1 strain has
shown that cross-reactivity is stronger when assessed by the more
sensitive neutralisation assay [23] which provides an evaluation of
the vaccine activity against both the HA and the NA antigens and
consequently, gives a more comprehensive evaluation of the
biological activity of the vaccine. This was confirmed in this present
study for the recombinant A/turkey/Turkey/1/2005 and A/
Anhui/1/2005 strains.
A recent pre-clinical study provides further evidence that
vaccination with H5 and N1 antigens from one clade can induce a
broadly protective immune response against wild type viruses from
another clade [28]. Suguitan and colleagues showed that vaccines
developed from attenuated strains containing H5 and N1
components from 1997 clade 3, 2003 clade 1 or 2004 clade 1
isolates protected mice from lethal challenge with both homolo-
gous and heterologous wild type viruses including more recent
2005 clade 1 and clade 2 viruses [28]. Similar data were generated
for protection against pulmonary replication following challenge
with these different strains in vaccinated mice and ferrets. The
authors suggested that the high level of protection afforded by
vaccination with the 1997 clade 3 vaccine against challenge with
the clade 1 and clade 2 H5N1 viruses isolated over a span of 8
years, indicates that the H5N1 viruses are evolving to infect
different birds, and not predominantly to evade antibodies as they
do in humans [28]. Earlier evidence that an avian influenza
vaccine could exhibit cross-immunity came from a study where a
surface-antigen vaccine based on the antigenically related H5N3
influenza virus (influenza A/duck/Singapore/97) and adjuvanted
with MF59 induced cross-reactive antibodies against H5N1 [29].
Whereas we did not observe any cross-reactive response following
administration of two doses of non-adjuvanted vaccine, these
authors did measure some degree of cross-reactivity after three
doses of non-adjuvanted vaccine.
We have previously demonstrated the significant antigen dose-
sparing effect of including an oil-in-water emulsion based adjuvant
system in the candidate vaccine formulation [23]. This is now re-
enforced by the results of this present study which confirm that the
adjuvant enhances the effectiveness of a low antigen dose in
broadening the immune response. Baras et al [30] recently
documented in a stringent preclinical model that the AS adjuvanted
candidate vaccine described inthe present paper provides protection
against cross-clade heterologous challenge in ferrets. The availability
of H5N1 vaccines that can elicit a broad cross-protective immunity
against different currently circulating H5N1 viruses, including newly
emerged strains, is a pre-requisite for the development of a successful
pre-pandemic vaccination strategy. Deployment of such vaccines for
pre-emptive vaccination could play a key role in pandemic
mitigation during the several months that it would take to produce
an H5N1 vaccine exactly matched to a pandemic strain.
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